by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
RVd (lenalidomide, bortezomib, and dexamethasone) continues to represent the standard of care even for older patients, for whom other triplets are ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Pomalidomide-based combinations and anti-CD38–directed therapies are among those that have been shown to be effective in patients with relapsed and......READ MORE
Lenalidomide-based triplet therapy is standard in the treatment of multiple myeloma. An all-oral triplet, with ixazomib instead of bortezomib, may ......READ MORE
Post-transplant lenalidomide maintenance therapy has improved outcomes in standard-risk and high-risk patients with multiple myeloma. As investigat......READ MORE
Continuous antimyeloma therapy has been shown to prolong disease control and has replaced the fixed-duration approaches of the past. Ideal properti......READ MORE
Proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) constitute the backbone of current therapeutic approaches that offer a survival adva......READ MORE
